INSIGHTS ON DRUG DEVELOPMENT
-
Rapid Walkaway Solution For Assessing Viability In Cancer Organoids
Assess anti-cancer compounds' effects on organoid size and morphology with colorectal cancer organoids as well as discover automated imaging and viability assays to streamline drug screening and aid early identification.
-
Overcoming Challenges In Ophthalmic Formulations
Discover key strategies for overcoming formulation challenges in ophthalmic drug development and learn how selecting the right excipients supports quality, compliance, and safety.
-
Biologic Stability: A Thermofluor Screen For Rational Buffer Optimization
Learn how thermal shift fluorimetry (thermofluor) can be used as a rapid, low-volume, and cost-effective technique to accelerate buffer optimization and enhance protein stability.
-
Lipid Nanoparticles For Pulmonary Delivery Of mRNA
Gain insight into how nebulized mRNA lipid nanoparticles show preclinical success in lung delivery, offering fresh momentum for inhaled gene therapies targeting respiratory diseases.
-
Enhancing Throughput And Reproducibility In Proteomic Analysis8/27/2025
Streamline proteomic workflows with consistent sample preparation. Discover how simplifying LC-MS processes can eliminate bottlenecks, improve reproducibility, and accelerate drug discovery research.
-
Safety Of Injectables: Ensuring Purity Via Endotoxin Testing7/28/2026
Advance pharmaceutical quality and sustainability by adopting recombinant factor C testing for reliable, animal-free endotoxin detection.
-
De-Risking Drug Development: Informatics-Supported Solid Form Selection5/6/2026
Learn how combining polymorph screening with structural informatics improves solid‑form selection, lowers development risk, and boosts confidence in long‑term stability and manufacturability.
-
Imagine The Future: An Enhanced Oligonucleotide Synthesis Process2/9/2026
Gain practical guidance for improving oligo quality, see how an advanced synthesis platform supports production, and explore a software interface designed to make daily operations more intuitive.
-
Analyzing Biological Drug Effects In 3D10/24/2025
Explore how 3D tumor microtissues paired with fluorescence-based assays offer scalable, high-sensitivity drug testing to deliver stronger signals and reproducible results compared to monolayer cultures.
DRUG DEVELOPMENT SOLUTIONS
-
Leica M205 A - Total recall of your settings
Your goal: high-quality images that allow measurements and can be accurately repeated with minimal effort. The Leica coded stereo microscopes help you to pave the way to correct results.
-
Coded microscopes consistently deliver calibrated and comparable images
-
Reproduce images in moments with the Leica “Store and Recall” function
-
Fully apochromatic corrected zoom optics deliver high quality images
-
Customize the microscope system to your task with the exclusive range of accessories
-
-
Ergonomic system microscope Leica DM1000 LED
The Leica DM1000 LED features long-life LED illumination that provides near daylight, bright illumination with constant color temperature and emits less heat.
The LED also eliminates the need for lamp changes, which saves time and money. Because of its low power consumption, the system is energy efficient. Users of the Leica DM1000 LED benefit from the system’s ability to uniquely adapt to every user.
It is ideal for all clinical laboratory applications, especially for cytology, haematology, and pathology. For special diagnostics requirements, the microscope is certified for in-vitro-diagnostics (IVD) like in-vitro-fertilization (IVF).
-
Find what you need to move your Alzheimer’s research forward faster, with antibodies to 95% of core AD genes validated in imaging applications with human samples.
-
Cambrex holds US Drug Enforcement Agency (DEA) licenses for process research, development, manufacturing, and importation of Schedule I to IV controlled substances.
-
Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.